


RECD 10 MAY 2001

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 17810-509		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/05402	International filing date (day/month/year) 25/02/2000	Priority date (day/month/year) 26/02/1999	
International Patent Classification (IPC) or national classification and IPC C12N5/08			
Applicant CYTOTHERAPEUTICS, INC. et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 4 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 5 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>			
Date of submission of the demand 26/09/2000		Date of completion of this report 08.05.2001	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer Marinoni, J-C Telephone No. +49 89 2399 8563	



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/05402

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-14 as originally filed

Claims, No.:

1-34 with telefax of 27/03/2001

Drawings, sheets:

1/1 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/05402

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-34
	No:	Claims	None
Inventive step (IS)	Yes:	Claims	1-34
	No:	Claims	None
Industrial applicability (IA)	Yes:	Claims	1-34
	No:	Claims	None

2. Citations and explanations
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/05402

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:
D1: US-A-5 750 376, 12 May 1998; cited in the application
D2: WO 96 04368, 15 February 1996
D3: WO 96 15226, 23 May 1996
D4: WO 94 09119, 28 April 1994
D5: US-A-5 411 883, 2 May 1995
D6: US-A-5 342 777, 30 August 1994
2. The present application relates to methods of proliferation of neural stem cell culture comprising the steps of dissociating neural tissue, inducing proliferation by using a proliferation-inducing growth factor and passaging cells by collagenase treatment.
3. None of the cited documents discloses or even suggests such a method. Although **D1-D4** relate to methods of proliferation of neural stem cell culture comprising the steps of dissociating neural tissue and inducing proliferation by using a proliferation-inducing growth factor, they fail to mention or even suggest the use of collagenase when passaging the cells. In **D5** trypsin is used when passaging the cells and the use of another compound is not suggested. **D6** relates to human liver epithelial cell culture and passaging by collagenase treatment. However, there is no hint in **D6** that the technique could be used successfully for other cell types.
4. Therefore, the subject-matter of **claims 1-34** meets the requirement of Article 33(2) PCT concerning novelty and of Article 33(3) PCT concerning inventive step.

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 17810-509	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 00/ 05402	International filing date (day/month/year) 25/02/2000	(Earliest) Priority Date (day/month/year) 26/02/1999
Applicant CYTOTHERAPEUTICS, INC. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of Invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N5/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 5 750 376 A (REYNOLDS BRENT ET AL) 12 May 1998 (1998-05-12) cited in the application abstract column 1, line 39 - line 56 column 10, line 58 - column 11, line 4 column 11, line 29 - line 41 column 15, line 64 - column 18, line 5 column 18, line 42 - column 23, line 5 column 30, line 20 - column 34, line 55; examples 3-5, 7, 20-23</p> <p style="text-align: center;">--- -/--</p>	1-37



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

1 August 2000

Date of mailing of the international search report

07/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Noë, V

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 04368 A (UNIV DALHOUSIE) 15 February 1996 (1996-02-15) page 2, line 10 -page 5, line 20 page 6, line 1 - line 22 page 7, line 12 - line 16 page 7, line 26 -page 8, line 12 page 11, line 6 - line 10 page 13, line 9 -page 15, line 9 example 1 ----	1-37
A	WO 96 15226 A (NEUROSPHERES HOLDINGS LTD ;WEISS SAMUEL (CA); REYNOLDS BRENT A (CA) 23 May 1996 (1996-05-23) page 8, line 25 -page 9, line 16 page 12, line 12 -page 13, line 7 page 16, line 6 - line 15; examples 1,5 ----	1-37
A	WO 94 09119 A (NEUROSPHERES LTD) 28 April 1994 (1994-04-28) page 8, line 12 -page 11, line 7 ----	1-37
A	US 5 411 883 A (BOSS BARBARA D ET AL) 2 May 1995 (1995-05-02) column 7, line 28 -column 8, line 9 column 12, line 17 - line 38 column 13, line 33 -column 14, line 6; examples 6,8 ----	1-37
A	US 5 342 777 A (HARRIS CURTIS C ET AL) 30 August 1994 (1994-08-30) column 10, line 16 - line 20 -----	

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5750376	A	12-05-1998	US 6071889 A	06-06-2000
			US 5981165 A	09-11-1999
			US 5980885 A	09-11-1999
			US 5851832 A	22-12-1998
			AU 697894 B	22-10-1998
			AU 8056194 A	29-05-1995
			CA 2175992 A	18-05-1995
			WO 9513364 A	18-05-1995
			CN 1141058 A	22-01-1997
			EP 0728194 A	28-08-1996
			FI 961855 A	04-06-1996
			JP 9507747 T	12-08-1997
			NO 961859 A	03-07-1996
			AU 714837 B	13-01-2000
			AU 3515295 A	09-04-1996
			CA 2200709 A	28-03-1996
			WO 9609543 A	28-03-1996
			EP 0783693 A	16-07-1997
			FI 971168 A	20-03-1997
			JP 10505754 T	09-06-1998
			NO 971245 A	18-03-1997
			AU 716811 B	09-03-2000
			AU 3836795 A	06-06-1996
			WO 9615226 A	23-05-1996
			CN 1170435 A	14-01-1998
			EP 0792350 A	03-09-1997
			FI 971956 A	04-07-1997
			JP 10509592 T	22-09-1998
			NO 972171 A	07-07-1997
			AU 665012 B	14-12-1995
			AU 2242592 A	11-02-1993
			CA 2113118 A	21-01-1993
			WO 9301275 A	21-01-1993
			EP 0594669 A	04-05-1994
			FI 935929 A	02-02-1994
			JP 6509225 T	20-10-1994
			NO 940056 A	03-03-1994
			WO 9416718 A	04-08-1994
			AU 683023 B	30-10-1997
			AU 5147493 A	09-05-1994
			CA 2147162 A	28-04-1994
			WO 9409119 A	28-04-1994
			EP 0664832 A	02-08-1995
			FI 951677 A	07-04-1995
			JP 8502172 T	12-03-1996
			NO 951378 A	07-04-1995
			AU 703729 B	01-04-1999
			AU 4924197 A	12-03-1998
			AU 5367694 A	24-05-1994
WO 9604368	A	15-02-1996	AU 3338595 A	04-03-1996
WO 9615226	A	23-05-1996	AU 716811 B	09-03-2000
			AU 3836795 A	06-06-1996
			CN 1170435 A	14-01-1998
			EP 0792350 A	03-09-1997
			FI 971956 A	04-07-1997
			JP 10509592 T	22-09-1998

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9615226	A		NO 972171 A	07-07-1997
			US 6071889 A	06-06-2000
			US 5750376 A	12-05-1998
			US 5980885 A	09-11-1999
			US 5851832 A	22-12-1998

WO 9409119	A	28-04-1994	AU 683023 B	30-10-1997
			AU 5147493 A	09-05-1994
			CA 2147162 A	28-04-1994
			EP 0664832 A	02-08-1995
			FI 951677 A	07-04-1995
			JP 8502172 T	12-03-1996
			NO 951378 A	07-04-1995
			WO 9416718 A	04-08-1994
			US 6071889 A	06-06-2000
			US 5750376 A	12-05-1998
			US 5980885 A	09-11-1999
			US 5851832 A	22-12-1998

US 5411883	A	02-05-1995	WO 9109936 A	11-07-1991

US 5342777	A	30-08-1994	US 5529920 A	25-06-1996
			AU 621972 B	26-03-1992
			AU 4815990 A	10-07-1990
			CA 2005494 A	14-06-1990
			EP 0449950 A	09-10-1991
			IL 92703 A	21-10-1994
			JP 3504330 T	26-09-1991
			US 5665589 A	09-09-1997
			WO 9007007 A	28-06-1990
			US 5759765 A	02-06-1998



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 5/08	A1	(11) International Publication Number: WO 00/50572 (43) International Publication Date: 31 August 2000 (31.08.00)
(21) International Application Number: PCT/US00/05402 (22) International Filing Date: 25 February 2000 (25.02.00) (30) Priority Data: 09/258,529 26 February 1999 (26.02.99) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/258,529 (CON) Filed on 26 February 1999 (26.02.99) (71) Applicant (for all designated States except US): CYTOTHERAPEUTICS, INC. [US/US]; 525 Del Rey Avenue, Suite C, Sunnyvale, CA 94086 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): UCHIDA, Nobuko [JP/US]; 223 High Street, Palo Alto, CA 94301 (US). (74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF COLLAGENASE IN THE PREPARATION OF NEURAL STEM CELL CULTURES (57) Abstract The invention provides a method for using collagenase to dissociate neural stem cells in neural stem cell cultures. The collagenase treatment results in an increased cell viability and an increased number of proliferated neural stem cells over time.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number
WO 00/50572 A1

- (51) International Patent Classification⁷: C12N 5/08
- (21) International Application Number: PCT/US00/05402
- (22) International Filing Date: 25 February 2000 (25.02.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/258,529 26 February 1999 (26.02.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/258,529 (CON)
Filed on 26 February 1999 (26.02.1999)
- (71) Applicant (for all designated States except US): CY-
TOTHERAPEUTICS, INC. [US/US]; 525 Del Rey
Avenue, Suite C, Sunnyvale, CA 94086 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): UCHIDA, Nobuko
[JP/US]; 223 High Street, Palo Alto, CA 94301 (US).
- (74) Agent: ELRIFL, Ivor, R.; Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., One Financial Center, Boston,
MA 02111 (US).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (48) Date of publication of this corrected version:
30 August 2001
- (15) Information about Correction:
see PCT Gazette No. 35/2001 of 30 August 2001, Section
II
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF COLLAGENASE IN THE PREPARATION OF NEURAL STEM CELL CULTURES

(57) Abstract: The invention provides a method for using collagenase to dissociate neural stem cells in neural stem cell cultures. The collagenase treatment results in an increased cell viability and an increased number of proliferated neural stem cells over time.

WO 00/50572 A1

USE OF COLLAGENASE IN THE PREPARATION OF NEURAL STEM CELL CULTURES

CLAIM OF PRIORITY

5 This invention claims priority to United States patent application 09/258,529, filed February 26, 1999.

TECHNICAL FIELD

10 This invention relates generally to a production or manufacturing process for the *in vitro* proliferation and culture of neural stem cell cultures using collagenase to dissociate the cultured cells.

BACKGROUND OF THE INVENTION

15 The development of the mammalian central nervous system (CNS) begins in the early stage of fetal development and continues until the post-natal period. The mature mammalian CNS is composed of neuronal cells (neurons), and glial cells (astrocytes and oligodendrocytes). The first step in neural development is cell birth, which is the precise temporal and spatial sequence in which stem cells and stem cell progeny (*i.e.* daughter stem cells and progenitor cells)
20 proliferate.

One identifying feature of a stem cell is its ability to exhibit self-renewal or to generate more of itself. A definition of a stem cell is provided by Potten & Loeffler, 110 Development 1001 (1990) who have defined stem cells as "undifferentiated cells capable of (a) proliferation, (b) self-maintenance, (c) the production of a large number of differentiated functional progeny,
25 (d) regenerating the tissue after injury, and (e) a flexibility in the use of these options." The role of stem cells is to replace cells that are lost by natural cell death, injury or disease.

United States patents 5,750,376, 5,851,832 (both naming Weiss) and 5,753,506 (Johe), each incorporated herein by reference, refer to *in vitro* cultures containing neural stem cells. The Weiss patents refer to both suspension and adherent culture, while Johe refers to particular
30 adherent cultures. When the cells are propagated as neurospheres in suspension culture, within 3-4 days in the presence of a proliferation-inducing growth factor, a multipotent neural stem cell begins to divide giving rise to a cluster of undifferentiated cells referred to as a "neurosphere". The cells of a single neurosphere are clonal in nature because they are the progeny of a single

neural stem cell. In the continued presence of one or more proliferation-inducing growth factors, such as EGF, bFGF, or the like (and combinations thereof), cells within the neurosphere continue to divide resulting in an increase in the size of the neurosphere and the number of undifferentiated cells. The cells within the neurosphere are immunoreactive for nestin, an intermediate filament protein found in many types of undifferentiated CNS cells. In contrast, mature differentiated cell types derived from the neural stem cell progeny are predominantly negative for nestin.

In the prior art, the cells in the cluster were mechanically dissociated by trituration to produce single cells between passages. Trituration, because it is a mechanical process, exerts shear forces on the cells, that may reduce cell viability between passages. The object of the present invention is to provide an improved culture and manufacture process that increases cell viability from passage to passage and maintains more of the most primitive cells (with the greatest differentiation potential and self-renewal capability).

SUMMARY OF THE INVENTION

The invention provides a method for the *in vitro* proliferation of multipotent neural stem cell culture using collagenase to dissociate cells in neurospheres between passages. According to the method of this invention, use of collagenase results in improved neural stem cell culture viability, increased number of proliferated cells in those cultures over time, and improved maintenance of cell cultures, as compared with dissociation by trituration or other enzymatic treatments such as trypsinization.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a comparison between the prior art trituration method of dissociating proliferating human neurospheres and the collagenase method of the invention, demonstrating an increased number of viable cells over time using the collagenase method.

DETAILED DESCRIPTION OF THE INVENTION

Introduction. The invention provides a novel manufacturing process for proliferating neural stem cell cultures, using collagenase to dissociate neurospheres ("aggregated" cells). This method results in an unexpectedly improved neural stem cell culture viability and increased

number of proliferated cells over time, as compared with prior art trituration and trypsinization methods for dissociating neural stem cell cultures.

In one embodiment of the collagenase manufacture process, neurosphere cells are harvested and centrifuged (*e.g.*, at 1000 rpm for 3-5 min). After aspirating medium, neurospheres are resuspended in collagenase solution (*e.g.*, 1 ml of pre-warmed (37°C) 0.5 mg/ml), and incubated with the collagenase. After the incubation, cell suspension is diluted in medium and cultured.

In the prior art trituration method, neurosphere cells were harvested and centrifuged. After aspirating medium, neurospheres were resuspended in ~200 µl of medium. Neurospheres were trituated by using a pipette (*e.g.*, a P200 pipetman with 75 µl volumes, about 100 times). Then, the cell suspension was diluted in medium and cultured.

Collagenase. Any collagenase which is effective for dissociating neural stem cells in culture may be used in the manufacture process of the invention. "Collagenase" is an enzyme that digests the extracellular matrix protein collagen (Harper, 49 Ann. Rev. Biochem. 1063 (1980)). One source of collagenase is the bacterium *Clostridium histolyticum*. One collagenase assay is a modification of Mandl *et al.*, 32 J. Clin. Invest. 1323 (1953), whereby collagenase is incubated for 5 hr with native collagen. The extent of collagen breakdown is determined using the colorimetric ninhydrin method of Moore & Stein, 176 Biol. Chem 367 (1948). For collagenase unit definition, 1 unit releases one µmole of L-leucine equivalents from collagen in 5 hr at 37°C, pH 7.5.

Crude collagenases can be used for cell dissociation procedures. Crude collagenase preparations contain not only several collagenases but also a sulfhydryl protease, clostripain, a trypsin-like enzyme, and an aminopeptidase. In some embodiments, we prefer crude collagenase preparations, because of the presence of these additional activities. This combination of collagenolytic and proteolytic activities is effective at breaking down intercellular matrices, the essential part of tissue dissociation. Crude collagenase is inhibited by metal chelating agents such as cysteine, EDTA or o-phenanthroline. It is also inhibited by alpha-2-macroglobulin, a large plasma glycoprotein. Ca²⁺ is thought to be required for enzyme activity.

Commercially-available sources of collagenase are useful in the methods of this invention. For example, purified collagenase contains minimal secondary proteolytic activities, but with high collagenase activity. Purified collagenase can be collagenase H (Cat # 1 087 789) from Boehringer Mannheim (Indianapolis, IN). A stock solution of 0.5 mg/ml collagenase is prepared in DPBS containing 0.1 % BSA, and stored -20°C. Other commercially available sources

are Dispase (Boehringer Mannheim), Liberase (Boehringer Mannheim) or collagenase (Serva). The range of collagenase used can be from 100-1000 $\mu\text{g/ml}$ (18-180 mU/ml), preferably between 300 - 700 $\mu\text{g/ml}$, (54-126 mU/ml) most preferably about 500 $\mu\text{g/ml}$ (90 mU/ml).

Isolation and In Vitro Proliferation of Multipotent Self-renewing CNS Neural Stem Cells

5 Neurobiologists have used various terms interchangeably to describe the undifferentiated cells of the CNS. Terms such as "stem cell", "precursor cell", and progenitor cell" were once used in the scientific literature. However, there are different types of undifferentiated neural cells, with differing characteristics and fates. The terminology used for undifferentiated multipotent neural cells has evolved such that these cells are now termed "neural stem cells" United States patent 10 5,750,376 defines the "neural stem" cell proliferated *in vitro* to mean "an oligopotent or multipotent stem cell which is able to divide without limit and under specific conditions can produce daughter cells which terminally differentiate into neurons and glia." The capability of a cell to divide without limit and produce daughter cells which terminally differentiate into neurons and glia are CNS stem cell characteristics. A CNS neural stem cell is capable of self 15 maintenance, meaning that with each cell division, one daughter cell will also be a stem cell. A CNS neural stem cell can be induced to proliferate using the methods of the present invention.

The non-stem cell progeny of a neural stem cell may include progenitor cells. The progenitor cells generated from a single multipotent self-renewing CNS neural stem cell are capable of differentiating into neurons, astrocytes (type I and type II) or oligodendrocytes. By 20 contrast, the CNS neural stem cell is "multipotent" because its progeny have multiple differentiative pathways.

A "neural progenitor cell" is an undifferentiated cell derived from a multipotent self-renewing CNS neural stem cell, and is not itself a stem cell. Some progenitor cells can produce progeny that are capable of differentiating into more than one cell type. For example, an O-2A 25 cell is a glial progenitor cell that gives rise to oligodendrocytes and type II astrocytes, and thus could be termed a "bipotent" progenitor cell. A distinguishing feature of a progenitor cell is that, unlike a stem cell, it has limited proliferative ability and thus does not exhibit self maintenance. It is committed to a particular path of differentiation and will, under appropriate conditions, eventually differentiate into glia or neurons.

30 The term "precursor cells" refers to the progeny of multipotent self-renewing CNS neural stem cells, and thus includes both progenitor cells and daughter multipotent self-renewing CNS neural stem cells.

Multipotent self-renewing CNS neural stem cells can be obtained from embryonic, post-natal, juvenile or adult neural tissue. The preferred source neural tissue is from mammals, preferably rodents (e.g., mice and rats) and primates, and most preferably, from humans. Method for the isolation, proliferation, and passaging of multipotent self-renewing CNS neural stem cells from adult human neural tissue, embryonic human neural tissue, adult monkey (*Rhesus*) neural tissue, mouse embryonic neural tissue, and juvenile and adult mouse brain tissue, including the establishment of neural stem cells in culture from CNS neural stem cells as well as the differentiation of the CNS neural stem cell progeny, are provided by Weiss *et al.*, United States patents 5,750,376 and 5,851,832 (each incorporated herein by reference). In the method of the present invention however, neurospheres are collagenase-treated to dissociate the aggregated cells, rather than triturated or trypsinized according to the methods used by Weiss *et al.*, United States patents 5,750,376 and 5,851,832 and Johe, United States patent 5,753,506 (each incorporated herein by reference).

Multipotent self-renewing CNS neural stem cells can be obtained from donor tissue by dissociation of individual cells from the connecting extracellular matrix of the tissue, as described by Weiss *et al.*, United States patents 5,750,376 and 5,851,832 and Johe, United States patent 5,753,506. Tissue is removed from a neural region using a sterile procedure, and the cells are dissociated in tissue culture medium using any method known in the art including treatment with enzymes such as trypsin, collagenase and the like, or by using physical methods of dissociation such as with a blunt instrument, as described by Weiss *et al.*, United States patents 5,750,376 and 5,851,832. Dissociated cells are centrifuged at low speed, between 200 and 2000 rpm, usually between 400 and 1000 rpm, and then resuspended in culture medium. The neural cells can be cultured in suspension or on a fixed substrate. Cell suspensions are seeded in any receptacle capable of sustaining cells, particularly culture flasks, culture plates or roller bottles, and more particularly in small culture flasks such as 25 cm² culture flasks. Cells cultured in suspension are resuspended at approximately 5×10^4 to 1×10^6 cells/ml, preferably 1×10^6 cells/ml (for 20 week g.w. tissue). Cells plated on a fixed substrate are plated at approximately 2×10^3 to 10^4 cells/cm², preferably 2.5×10^3 cells/cm².

Collagenase-treated neural stem cell cultures, including the multipotent self-renewing CNS neural stem cells of the neurospheres, can be proliferated either on substrates or in suspension, preferably forming clusters of associated undifferentiated cells, referred to as "neurospheres." After culture in the absence of a substrate, the proliferating neurospheres lift off

the floor of the culture dish and tend to form the free-floating clusters characteristic of neurospheres. The proliferating precursor cells of the neurosphere continue to proliferate in suspension. The neurospheres of the suspension culture can be easily passaged to reinitiate proliferation. In the method of the invention, individual cells in the neurospheres are separated by collagenase treatment. The collagenase-treated neurosphere cells are then replated at the desired density to reinitiate proliferation. Single cells from the dissociated neurospheres are suspended in culture medium containing growth factor, and a percentage of these cells proliferate and form new neurospheres largely composed of undifferentiated cells. This manufacture process can be repeated to result in a logarithmic increase in the number of viable cells at each passage. The procedure is continued until the desired number of cells is obtained.

Weiss *et al.*, United States patents 5,750,376 and 5,851,832 disclose "culture medium containing one or more predetermined growth factors effective for inducing multipotent neural stem cell proliferation." However, different basal media can be used, including, but not limited to:

D-MEM/F12 (Gibco BRL, Gaithersburg, MD);
Ex Vivo 15 (Bio Whittaker, Walkersville, MD);
Neural progenitor basal media, (Clonetics, San Diego, CA); or
combination of the basal media listed above.

The culture medium is supplemented with at least one proliferation-inducing growth factor. As used herein, the term "growth factor" refers to a protein, peptide or other molecule having a growth, proliferative, differentiative, or trophic effect on neural stem cells and/or neural stem cell progeny. Growth factors which may be used for inducing proliferation include any trophic factor that allows neural stem cells and precursor cells to proliferate, including any molecule which binds to a receptor on the surface of the cell to exert a trophic, or growth-inducing effect on the cell. Preferred proliferation-inducing growth factors include members of the EGF superfamily, FGF superfamily, and TGF α superfamily, such as EGF, amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor (bFGF or FGF-2), transforming growth factor alpha (TGF α), leukocyte inhibitory factor (LIF), glycostatin C and combinations thereof. A preferred combination of proliferation-inducing growth factors is EGF or TGF α with FGF-1 or FGF-2. Growth factors are usually added to the culture medium at concentrations ranging between about 1 fg/ml to 1 mg/ml. Concentrations between about 1 to

100 ng/ml are usually sufficient. Simple titration experiments can easily be performed to determine the optimal concentration of a particular growth factor.

The optimization of media formulation permits a higher percentage of neurospheres initiated from primary brain tissue to be established. We prefer Ex Vivo 15 media. The optimization of media formulation also permits a more consistent growth of neurospheres. To maximize neurosphere development, the collagenase-treated neurosphere cells are typically cultured in the presence of LIF, bFGF, EGF, and neural survival factor, NSF (Cat. CC-4323, Clonetics, San Diego, CA).

A typical media formulation to culture human neural stem cell cultures is provided in TABLE 1.

TABLE 1
Serum-Free N2/EGF Supplemented Culture Medium For Neural Stem Cell Cultures

Quantity	Reagents
87 ml	DMEM/F12 (Gibco lot. 1012915; Cat. No. 11330-032)
1 ml	N-2 Supplement (Gibco lot 1017018; Cat. No. 17502-014)
1 ml	0.2 mg/ml heparin (Sigma lot 28H0320; Cat. No. H-3149)
1 ml	0.2 M Glutamine (JCR lot 7N2320; Cat. No. 59202-77p)
10 ml	3 % Glucose (Sigma, lot 37H0841; Cat. No. G-7021)
20 µl	100 µg/ml EGF (R&D lot CE107091; Cat. No. 236-EG)
100 µl	20 µg/ml FGF-2 (Gibco lot KCQ411; Cat. No. 13256-029)
100 µl	10 µg/ml LIF (R&D lot OX038021; Cat. No. 250-L)

EGF is added to 100 ml base medium for human neural stem cell cultures after filtering the medium. EGF is relatively stable in the medium. FGF-2 and LIF are added when medium is ready to use. The final concentrations of the supplement reagents are:

TABLE 2

5 μ g/ml	Insulin
100 μ g/ml	Human transferrin
6.3 ng/ml	Progesterone
16.1 μ g/ml	Putrascine
5.2 ng/ml	Selenite
20 ng/ml	EGF
20 ng/ml	FGF-2
10 ng/ml	LIF
2 μ g/ml	heparin
2 mM	L-glutamine
6 mg/ml	Glucose

Collagenase-treated neural stem cell cultures can also be differentiated using the differentiation paradigms as described in Weiss *et al.*, United States patents 5,750,376 and 5,851,832. For example, (1) collagenase-treated neural stem cell cultures can be differentiated by a rapid differentiation after being plated on poly-L-ornithine-coated glass coverslips in medium containing 0.5% fetal bovine serum (FBS); (2) collagenase-treated neural stem cell cultures can be differentiated using dissociated neurospheres in EGF-free complete medium containing 1% FBS; (3) collagenase-treated neural stem cell cultures can be differentiated using single neurospheres plated onto laminin-coated glass coverslips; (4) collagenase-treated neural stem cell cultures can be differentiated using single dissociated neurospheres, collagenase-treated, and plated onto a 35 mm culture dish; (5) collagenase-treated neural stem cell cultures can be differentiated using neurospheres co-cultured with striatal astrocytes. In a preferred method of differentiation, neurosphere cells are plated on a laminin coated substrate in the presence of FBS. The resulting differentiated cells are probed by indirect immunocytochemistry for the presence of neuron, astrocytes and oligodendrocytes, for example, using antibodies to MAP-2, tau-1, neurofilament 168 kDa, β -tubulin, GABA, substance P (neuronal markers), GFAP (astrocytic marker), O4, and MBP (oligodendrocyte markers). All three neural cell types are expected to be identified.

Genetic Modification of Collagenase-treated Neural Stem Cell Cultures. The neural stem cell cultures described herein may be genetically modified according to any suitable method known in the art, including *in vitro* genetic modification, or generation of genetically modified neural stem cell cultures from transgenic mammals. The genetic modification of neural stem cells is performed either by infection with recombinant retroviruses or transfection using

methods known in the art (*see, Sambrook et al., Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory, N.Y., 1989). Methods of making genetically modified neural stem cells cultures are described, e.g., Weiss, United States patent 5,750,376, incorporated herein by reference.

5 Generally, the term "genetic modification" refers to the stable or transient alteration of the genotype of a precursor cell by intentional introduction of exogenous DNA. DNA may be synthetic, or naturally derived, and may contain genes, portions of genes, or other useful DNA sequences. The term "genetic modification" includes various gene activation methods known in the art. See, e.g., United States patents 5,733,761 and 5,733,746, each herein incorporated by
10 reference.

 In certain embodiments the neural stem cells are genetically modified to produce a biologically active molecule, including hormones, enzymes, neurotransmitters, antibodies, cytokines, lymphokines, growth factors, trophic factors, or biological response modifiers. Alternatively the neural stem cells are genetically modified to provide a metabolic or
15 immunologic function upon implantation in a host, preferably a human. It may also be desired to genetically modify cells so they secrete a certain growth factor product. The term "growth factor product" refers to a protein, peptide, mitogen, or other molecule having a growth, proliferative, differentiative, or trophic effect (*e.g.*, NGF, BDNF, the neurotrophins, CNTF, amphiregulin, FGF-1, FGF-2, EGF, TGF~~α~~, TGF~~β~~s, PDGF, IGFs, and the interleukins).
20 Neurosphere progeny cells can also be modified to express a certain growth factor receptor (*e.g.*, p75 low affinity NGF receptor, CNTF receptor, the *trk* family of neurotrophin receptors, EGF-R, FGF-R, and amphiregulin receptors). Collagenase-treated neural stem cell cultures can be engineered to produce various neurotransmitters, neurotransmitter receptors, or neurotransmitter-synthesizing enzymes.

25 *Transplantation of Neural Stem Cell Cultures to Alleviate Human Disorders.*

 Collagenase-treated neural stem cell cultures can be produced and transplanted into mammalian hosts, preferably human patients, for the treatment of various disorders, both in the central nervous system ("CNS") and systemically. Cells are delivered to the subject by any suitable means known in the art. If delivered to the central nervous system, then the cells are administered
30 to a particular region using any method which maintains the integrity of surrounding areas of the brain, preferably by injection cannula. Injection methods exemplified by those used by Duncan *et al.*, 17 J. Neurocytology 351-361 (1988), and scaled up and modified for use in humans are

preferred. Methods for the injection of cell suspensions such as fibroblasts into the CNS may also be employed for injection of neural precursor cells. Additional approaches and methods may be found in *Neural Grafting in the Mammalian CNS*, Bjorklund & Stenevi, eds. (1985).

Collagenase-treated neural stem cell cultures can be produced and transplanted using the
5 above procedures to treat various neurodegenerative disorders. Such CNS disorders encompass numerous afflictions such as neurodegenerative diseases (*e.g.* Alzheimer's and Parkinson's), acute brain injury (*e.g.* stroke, head injury, cerebral palsy) and a large number of CNS dysfunctions (*e.g.* depression, epilepsy, and schizophrenia). In recent years neurodegenerative disease has become an important concern due to the expanding elderly population which is at
10 greatest risk for these disorders. These diseases, which include Alzheimer's Disease, Multiple Sclerosis (MS), Huntington's Disease, Amyotrophic Lateral Sclerosis, and Parkinson's Disease, have been linked to the degeneration of neural cells in particular locations of the CNS, leading to the inability of these cells or the brain region to carry out their intended function. By providing for maturation, proliferation and differentiation into one or more selected lineages through
15 specific different growth factors the progenitor cells may be used as a source of committed cells. In one series of embodiments, collagenase-treated neural stem cell cultures can be produced and transplanted using the above procedures for the treatment of demyelination diseases. Any suitable method for the implantation of cells near to the demyelinated targets may be used so that the cells can become associated with the demyelinated axons.

20 Neural stem cell cultures made according to the present invention may also be used to produce a variety of blood cell types, including myeloid and lymphoid cells, as well as early hematopoietic cells (*see*, Bjornson *et al.*, 283 SCIENCE 534 (1999), incorporated herein by reference).

In Vitro Models of CNS Development, Function and Dysfunction, and Methods for
25 *Screening Effects of Drugs on Cells.* Collagenase-treated neural stem cell cultures cultured *in vitro* can be used for the screening of potential neurologically therapeutic compositions. These compositions can be applied to cells in culture at varying dosages, and the response of the cells monitored for various time periods. Physical characteristics of the cells can be analyzed by observing cell and neurite growth with microscopy. The induction of expression of new or
30 increased levels of proteins such as enzymes, receptors and other cell surface molecules, or of neurotransmitters, amino acids, neuropeptides and biogenic amines can be analyzed with any technique known in the art which can identify the alteration of the level of such molecules. These

techniques include immunohistochemistry using antibodies against such molecules, or biochemical analysis. Such biochemical analysis includes protein assays, enzymatic assays, receptor binding assays, enzyme-linked immunosorbant assays (ELISA), electrophoretic analysis, analysis with high performance liquid chromatography (HPLC), Western blots, and radioimmune assays (RIA). Nucleic acid analysis such as Northern blots can be used to examine the levels of mRNA coding for these molecules, or for enzymes which synthesize these molecules. Alternatively, cells treated with these pharmaceutical compositions can be transplanted into an animal, and their survival, ability to form neuronal connections, and biochemical and immunological characteristics examined as previously described.

The collagenase-treated neural stem cell cultures can be used in methods of determining the effect of a biological agents on neural cells. The term "biological agent" refers to any agent, such as a virus, protein, peptide, amino acid, lipid, carbohydrate, nucleic acid, nucleotide, drug, pro-drug or other substance that may have an effect on neural cells whether such effect is harmful, beneficial, or otherwise. Biological agents that are beneficial to neural cells are referred to herein as "neurological agents", a term which encompasses any biologically or pharmaceutically active substance that may prove potentially useful for the proliferation, differentiation or functioning of CNS cells or treatment of neurological disease or disorder. To determine the effect of a potential biological agent on neural cells, a culture of collagenase-treated neural stem cell cultures is obtained and proliferated *in vitro* in the presence of a proliferation-inducing growth factor. Generally, the biological agent will be solubilized and added to the culture medium at varying concentrations to determine the effect of the agent at each dose. The culture medium may be replenished with the biological agent every couple of days in amounts, so as to keep the concentration of the agent somewhat constant.

Thus, it is possible to screen for biological agents that increase the proliferative ability of progenitor cells which would be useful for generating large numbers of cells for transplantation purposes. It is also possible to screen for biological agents which inhibit precursor cell proliferation, using collagenase-treated neural stem cell cultures. Also, the ability of various biological agents to increase, decrease or modify in some other way the number and nature of differentiated neural cells can be screened on collagenase-treated neural stem cell cultures that have been induced to differentiate. The effects of a biological agent or combination of biological agents on the differentiation and survival of differentiated neural cells can then be determined. It

is also possible to determine the effects of the biological agents on the differentiation process by applying them to collagenase-treated neural stem cell cultures prior to differentiation.

Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated by reference. The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. These examples should in no way be construed as limiting the scope of the invention, as defined by the appended claims.

EXAMPLE 1 COLLAGENASE PROTOCOL

1. Rinse tissue several times with Ca^{++} , Mg^{++} -free phosphate buffered saline (PBS).
2. In a Petri dish, cut tissue into 1-2 mm cubed pieces using crossed scalpels. Pour the tissue (packed volume ~7.5 ml) and PBS (~8 ml) into a 50 ml centrifuge tube. Rinse the dish with PBS as necessary to remove tissue, and transfer to the centrifuge tube.
3. Centrifuge the tubes gently to sediment the tissue and free cells (<1000 rpm).
4. Remove the supernatant carefully using a vacuum line.
5. For up to 1.0 g of tissue, add 5.0 ml 0.1% Collagenase, 0.1% Hyaluronidase in HBSS without Ca^{++} , Mg^{++} which contains 1.0% bovine serum albumin (BSA).
6. Incubate in 37°C waterbath with occasional light agitation for 1 hour. At the end of 1 hr, vortex for approximately 3 sec, and evaluate the extent tissue dissociation. If large pieces of intact tissue remains, continue incubation at 37°C for another 30-45 min. Stand the tube upright for 1-2 min to allow large cell aggregates to settle out. Transfer the supernatant to a fresh tube (1).
7. Top up the fresh tube (1) with PBS + 0.1% BSA and centrifuge at approximately 900 rpm for 6 min. Remove the supernatant, which should be cloudy with debris, to a fresh 50 ml centrifuge tube (2). Recentrifuge both tubes (1) and (2) at 900 rpm.

8. Discard the supernatant from tube (1) and examine the pellet from tube (2) for viable cells. If worthwhile, combine the pelleted cells from tube (2) with the contents of tube (1). Fill up the tube with PBS + 0.1% BSA and respin for 6 min at 900 rpm, discarding the supernatant when finished. Resuspend the cells in PBS and count with trypan blue. At this stage, the cell suspension should be relatively free of debris, and should consist predominantly of healthy cells.

EXAMPLE 2 COLLAGENASE RESULTS

Collagenase treatment provided increased number of viable neural stem cells using the collagenase method. Cells are counted in trypan blue on hemocytometer. A raw count is the number of live cells in defined area.

TABLE 3					
	Live	Dead	Cells/ml	Total cells	% viability
Collagenase	121	12	8.07×10^5	8.07×10^6	91
Trituration	45	49	3×10^5	3×10^6	48

Collagenase treatment provided increased number of proliferated neural stem cells over time using the collagenase method.

TABLE 4				
Days	Trituration	Collagenase Treatment	% Viability Trituration	% Viability Collagenase
0	2.00×10^6	2.00×10^6		
7	4.60×10^6	1.60×10^7	40.00%	89%
17	1.04×10^7	7.28×10^7	52.00%	93%
25	8.80×10^6	1.67×10^8	37.00%	78%
33	1.55×10^7	6.75×10^8	48.00%	91%
41	2.33×10^7	2.61×10^9	38.00%	98%
			Average	Average
			43.00%	90.0%
			$\pm 6.63\%$	$\pm 7.4\%$

TABLE 5						
Days	Trituration	Input Cell No.	Output Cell No.	% Viability	X Expansion	Accumulated Cell No.
0	P24-P1	2.00×10^6				2.00×10^6
7	P25-P2	2.00×10^6	4.60×10^6	40%	2.3	4.60×10^6
17	P26-P3	2.00×10^6	4.50×10^6	52%	2.3	1.04×10^7
25	P27-P4	2.00×10^6	1.70×10^6	37%	0.9	8.80×10^6
33	P28-P5	1.95×10^6	3.00×10^6	48%	1.8	1.55×10^7
41	P29-P6	2.00×10^6	3.00×10^6	38%	1.5	2.33×10^7
				Average		
				43%		

TABLE 6						
Days	Collagenase	Input Cell No.	Accumulated Cell No.	% Viability	X Expansion	Accumulated Cell No.
0	P24-P1	2.00×10^6				2.00×10^6
7	P25-P2	2.00×10^6	1.60×10^7	89%	8.0	1.60×10^7
17	P26-P3	2.00×10^6	9.70×10^6	93%	4.6	7.28×10^7
25	P27-P4	2.00×10^6	4.60×10^6	78%	2.3	1.67×10^8
33	P28-P5	1.70×10^6	8.06×10^6	91%	4.0	7.94×10^8
41	P29-P6	2.00×10^6	5.73×10^6	98%	3.9	2.27×10^9
				Average		
				90%		

The foregoing description has been presented only for the purposes of illustration and is not intended to limit the invention to the precise form disclosed, but by the claims appended hereto.

CLAIMS

WE CLAIM:

1. A method for the *in vitro* proliferation of a neural stem cell culture comprising the steps of:
 - (a) obtaining dissociated neural tissue in cell suspension, the suspension containing one or more multipotent neural stem cells capable of producing progeny that are capable of differentiating into neurons and glia;
 - (b) culturing the cell suspension in a culture medium containing at least one proliferation-inducing growth factor to proliferate the neural stem cells in (a) to generate a neural stem cell culture; and
 - (c) passaging the cell culture in (b) by treating the culture with an amount of a collagenase preparation effective to dissociate the cells in the culture and passing the cell culture to a culture medium containing at least one proliferation-inducing growth factor to further proliferate the neural stem cell culture.
2. The method of claim 1 wherein the amount of the collagenase preparation is between 18-180 mU/ml.
3. The method of claim 1 wherein the amount of the collagenase preparation is between 54-126 mU/ml.
4. The method of claim 1 wherein the collagenase preparation further comprises at least one molecule selected from the group consisting of sulfhydryl protease, clostripain, aminopeptidase, or combinations thereof.
5. The method of claim 1 wherein the collagenase preparation is substantially pure, and contains minimal secondary proteolytic activity.
6. The process of claim 1, wherein the proliferation-inducing growth factor is selected from the group consisting of epidermal growth factor, amphiregulin, acidic fibroblast growth factor, basic fibroblast growth factor, transforming growth factor alpha, leukocyte inhibitory factor (LIF), glycostatin C and combinations thereof.

7. The method of claim 1 wherein the neural stem cell culture comprises genetically modified

neural stem cells.

5

8. The method of claim 1, further comprising the step of differentiating the neural stem cell culture of (c) to produce a cell culture comprising differentiated neural cells selected from the group consisting of astrocytes, neurons, oligodendrocytes, and combinations thereof.

10

9. The method of claim 1 or claim 8, further comprising contacting the neural stem cell culture with a biological agent, and determining the effects of the biological agent on cells in the culture.

10. The method of claim 1 wherein the neural stem cell culture is a suspension culture.

15

11. The method of claim 1 wherein the neural stem cell culture is an adhesion culture.

12. The method of claim 1 wherein the neural stem cell culture comprises human neural stem cells.

20

13. A method for the *in vitro* proliferation of a neural stem cell culture comprising the steps of:
- (a) obtaining dissociated neural tissue in cell suspension, the suspension containing one or more multipotent neural stem cells capable of producing progeny that are capable of differentiating into neurons and glia;
 - (b) culturing the cell suspension in a culture medium containing at least one proliferation-inducing growth factor to proliferate the neural stem cells in (a) to generate a neural stem cell culture; and
 - (c) passaging the cell culture in (b) by treating the culture with an amount of a collagenase preparation effective to dissociate the cells in the culture and passing the cell culture to a culture medium containing at least one proliferation-inducing growth factor to further proliferate the neural stem cell culture, wherein the percent viability of the cells in the culture is at least 60% after being passaged.
14. The method of claim 13, wherein the percent viability of the cells in the culture is at least 75% after being passaged.
15. The method of claim 13, wherein the percent viability of the cells in the culture is at least 85% after being passaged.
16. The method of claim 13, wherein the amount of the collagenase preparation is between 18-180 mU/ml.
17. The method of claim 13, wherein the amount of the collagenase preparation is between 54-126 mU/ml.
18. The method of claim 13, wherein the collagenase preparation further comprises at least one molecule selected from the group consisting of sulfhydryl protease, clostripain, aminopeptidase, or combinations thereof.
19. The method of claim 13, wherein the collagenase preparation is substantially pure, and contains minimal secondary proteolytic activity.

20. The method of claim 13, wherein the neural stem cell culture comprises genetically modified neural stem cells.
- 5 21. The method of claim 13, further comprising the step of differentiating the neural stem cell culture of (c) to produce a cell culture comprising differentiated neural cells selected from the group consisting of astrocytes, neurons, oligodendrocytes, and combinations thereof.
22. The method of claim 13 wherein the neural stem cell culture is a suspension culture.
- 10 23. The method of claim 13 wherein the neural stem cell culture is an adhesion culture.
24. The method of claim 13 wherein the neural stem cell culture comprises human neural stem cells.
- 15 25. A cell culture made according to any one of claims 13-24.
26. A method for expanding a neural stem cell culture comprising the steps of:
- 20 (a) culturing a neural stem cell culture that contains one or more multipotent neural stem cells capable of producing progeny that are capable of differentiating into neurons and glia in a culture medium containing at least one proliferation-inducing growth factor to proliferate the culture; and
- (b) passaging the cell culture in (a) by treating the culture with an amount of a collagenase preparation effective to dissociate the cells in the culture and passing
- 25 the cell culture to a culture medium containing at least one proliferation-inducing growth factor to further proliferate the neural stem cell culture, wherein there is at least a three-fold increase in cell number between weekly passages.
27. The method of claim 26 wherein there is at least a five-fold increase in cell number
- 30 between weekly passages.
28. The method of claim 26 wherein the neural stem cell culture is a suspension culture.

29. The method of claim 26 wherein the neural stem cell culture is an adhesion culture.
30. The method of claim 26 wherein the neural stem cell culture comprises human neural stem cells.
31. A cell culture made according to any one of claims 26-30.
32. A method for expanding a neural stem cell culture comprising the steps of:
- (a) culturing a neural stem cell culture that contains one or more multipotent neural stem cells capable of producing progeny that are capable of differentiating into neurons and glia in a culture medium containing at least one proliferation-inducing growth factor to proliferate the culture; and
 - (b) passaging the cell culture in (a) by treating the culture with an amount of a collagenase preparation effective to dissociate the cells in the culture and passing the cell culture to a culture medium containing at least one proliferation-inducing growth factor to further proliferate the neural stem cell culture, wherein the accumulated cell number can be expanded from 10^6 cells to at least 10^9 cells in less than 49 days.
33. The method of claim 32 wherein the accumulated cell number can be expanded from 10^6 cells to at least 10^9 cells in less than 42 days.
34. The method of claim 32 wherein the neural stem cell culture is a suspension culture.
35. The method of claim 32 wherein the neural stem cell culture is an adhesion culture.
36. The method of claim 32, wherein the neural stem cell culture comprises human neural stem cells.
37. A cell culture made according to any one of claims 32-36.

1/1




Fig. 1